Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity


https://doi.org/10.4081/hmr.v2i5.383
Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update
Published: June 8, 2009
Abstract Views: 167
PDF: 1636
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

ortezomib (Velcade®) is the first of a new class of drugs known as proteasome-inhibitors. Its efficacy has been established in phase II trials SUMMIT and CREST and phase III trial APEX has demonstrated the superiority of Bortezomib (Velcade®) over high-dose dexamethasone in relapsed/refractory multiple myeloma (MM) patients. Although generally well tolerated, several side-effects are correlated to the administration of Bortezomib (Velcade®).

Supporting Agencies


Varettoni, M. (2009). Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.383
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC